1.     Why establish Ad-Vectors Biotech LLC?

The impact of COVID-19 continues to evolve. Now, efforts to prepare for future challenges, such as flu and RSV, remain a global priority. We established Ad-Vectors Biotech LLC to develop novel adenovirus vectors as a delivery vector for any possible drugs to fight against “Disease X” in the future, which represents a serious international epidemic caused by a pathogen currently unknown to cause human disease. Aside from “Disease X”, the WHO’s priority pathogens also include Ebola & Marburg virus diseases, Crimean-Congo hemorrhagic fever, Lassa fever, Severe Acute Respiratory Syndrome (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS), COVID (SARS-CoV-2), Nipah and other henipaviral diseases, Rift Valley fever, Zika virus, etc. We need to proactively get ready for the upcoming pandemic in the near future.

2.     Why choose adenovirus vectors?

There are strengths and limitations for all platforms based on adenovirus, AAV, lentivirus, mRNA, etc. However, AAV and lentivirus vectors and the mRNA platform possess inherent drawbacks that cannot be overcome. With our technologies to construct and engineer AdV vectors, we can overcome the adenovirus drawbacks and develop novel AdV vectors, which 1) can evade pre-existing immunity, 2) can induce a strong, long-lasting, cross-reactive immune responses after a single dose, 3) are safe to administer to the global population without the risk of rare side effects, and 4) are shelf-stable, cheap, highly scalable and capable of distribution to both first and third-world countries during next pandemic in the near future.